Últimas noticias sobre Equinox Gold (AMEX:EQX) Bolsa

Equinox Gold

Equinox Gold Corp is a mining company engaged in the operation, acquisition, exploration, and development of mineral properties, with a focus on gold. Equinox Gold has around seven operating gold mines and a clear plan to increase production by advancing the pipeline of growth projects. Geographically, the company operates in the United States, Mexico, and Brazil. The majority of its revenue is generated from Canada.

Gold,Bar,On,Candlestick,Chart,Background.,Conceptual,Image,Of,Gold

Equities

News

Commodities

Markets

Movers

PPTA

El oro se dispara y los inversores reaccionan. John Paulson aumenta su posición en mineras clave, mientras el mercado sigue su escalada.

Acciones de minería de oro en auge: los valores que dispararon la fortuna de John Paulson

Equinox Gold Corp

Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) recent transformation has led many to ask, &#8220;What exactly changed?&#8221; It is no longer just a speculative asset but a strategic macroeconomic instrument shaped by centralized institutions, sovereign wealth strategies, and <a href="https://www.benzinga.com/topic/bitcoin">long-term financial infrastructure.</a>
What Happened: American cryptocurrency exchange Gemini in an X <a href="https://x.com/Gemini/status/1936061491951587818">post </a>on Friday noted Bitcoin's pivotal shift occurred in March, when the United States officially launched its Strategic Bitcoin Reserve (SBR), elevating the crypto king to a sovereign-grade macro asset, on par with gold and oil.
This move marked the beginning of Bitcoin's institutional era, defined by structural inflows from sovereign and corporate treasuries, declining volatility and increased market stability
One key driver of this transformation is that over 30% of Bitcoin's circulating supply is now held by 216 centralized entities, including exchanges, ETFs/Funds, public and private companies, governments, and DeFi contracts.
Another factor is the concentration among top players: 65%–90% of Bitcoin in most institutional categories is controlled by the top 3 entities, with private companies being the only slightly more distributed segment. However, the early adopters still dominate and define institutional structure.
Gemini highlights that since 2018, Bitcoin's price swings have steadily calmed, making it more predictable and attractive to long-term capital. The 30.9% supply held by institutional treasuries adds structural support, helping suppress wild price movements.
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46027460/bitcoin-veteran-trader-goes-long-again-after-15-million-in-losses-will-third-time-be-the-charm">Bitcoin Veteran Trader Goes Long Again After $15 Million In Losses — Will Third Time Be The Charm?</a>
Why It Matters: Gemini also points to Bitcoin's reflexivity, meaning small capital inflows can drive disproportionate price increases. On average, $1 of investment adds $1.70 to Bitcoin's market capitalization, in bull markets, the impact rises to $3.70 and in short bursts, it can spike up to $25 per $1 invested.
This dynamic makes sovereign and institutional participation even more powerful, with potential to fuel self-reinforcing rallies.
In essence, Bitcoin is no longer just a speculative asset. It's becoming a strategic macroeconomic instrument, shaped by centralized institutions, sovereign wealth strategies, and long-term financial infrastructure.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46023419/bitcoin-ethereum-xrp-dogecoin-hold-steady-no-top-in-sight-plenty-of-room-to-grow">Bitcoin, Ethereum, XRP, Dogecoin Hold Steady: No Top In Sight, &#8216;Plenty Of Room To Grow&#8217;</a></li>
</ul>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin Quietly Entered A New Era In March: Here's What's Really Behind It

Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) on Friday <a href="https://dmdwarrior.com/capricor-therapeutics-announces-positive-4-year-data-of-deramiocel-cap-1002-in-duchenne-muscular-dystrophy/?_gl=1&#x2A;9g80lr&#x2A;_gcl_au&#x2A;MTgxMjM4ODIyNy4xNzUwMDg5NzEz&#x2A;_ga&#x2A;MTMzODE1NTQwNC4xNzM0MzgyMDk4&#x2A;_ga_MBTGG7KX5Y&#x2A;czE3NTA0NDUyNDkkbzQ1MiRnMSR0MTc1MDQ0NjQxOSRqMTUkbDAkaDExNjcwNDQzNDI.">released</a> four-year safety and efficacy results from its ongoing HOPE-2 Open-Label Extension (OLE) study of Deramiocel, the company&#8217;s lead cell therapy candidate for <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">Duchenne Muscular Dystrophy (DMD)</a>.
After four years of continuous treatment, Deramiocel-treated patients showed a median change of -0.5 points compared to baseline.
Further, a subgroup analysis of patients with baseline Left Ventricular Ejection Fraction (LVEF) >45% showed an even greater clinical benefit, supporting early intervention with Deramiocel to potentially preserve cardiac function.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44115317/capricor-therapeutics-cell-therapy-goes-under-priority-fda-review-for-duchenne-associated-heart-condition" rel="noreferrer noopener">Capricor Therapeutics Cell Therapy Goes Under Priority FDA Review For Duchenne Associated-Heart Condition</a>
Additionally, treatment continued to slow skeletal muscle disease progression, as measured by performance of the upper limb (PUL v2.0), with patients experiencing a smaller average decline in the fourth year (0.6 points) compared to the <a href="https://www.benzinga.com/pressreleases/25/06/g46025161/capricor-therapeutics-announces-positive-4-year-data-from-hope-2-open-label-extension-study-of-der" target="_blank" rel="noreferrer noopener">first year (1.8 points)</a>.
Together, these findings suggest that extended treatment with Deramiocel may help attenuate the progression of DMD over time. Deramiocel continues to maintain a favorable safety profile throughout the study.
&#8220;These four-year data reinforce the strength and durability of Deramiocel&#8217;s clinical benefit and favorable safety profile across both cardiac and skeletal muscle function,&#8221; said Linda Marbán, CEO of Capricor Therapeutics. &#8220;With our BLA under priority review and several key regulatory steps now completed, we are executing with focus and urgency as we move toward potential approval.
CAPR Price Action: CAPR stock is down 31.75% at $8.16 at publication on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/fda/25/06/45945282/sarepta-therapeutics-stock-plummets-over-40-on-second-fatal-case-linked-to-its-gene-therapy" target="_blank" rel="noreferrer noopener">Sarepta Therapeutics Stock Plummets Over 40% On Second Fatal Case Linked To Its Gene Therapy</a></li>
</ul>

Biotech

Health Care

Trading Ideas

General

CAPR

Capricor Reports 4-Year Data For Deramiocel, Shows Sustained Benefit In Duchenne Patients

Editor&#8217;s note: This article was updated to correct the details of the ETF.
<a href="https://www.benzinga.com/etfs">AI-themed ETFs</a> have proliferated in recent years, and many of them loaded with so-called &#8220;<a href="https://www.benzinga.com/topic/magnificent-seven">magnificent seven&#8221; tech giants</a>. 
However, not all are designed to endure the next innovation cycle. As the discussion moves from &#8220;what&#8217;s hot&#8221; to &#8220;what stands the test of time,&#8221; a new generation of ETFs is on the rise—those that adapt.
One such fund is the Dan IVES Wedbush AI Revolution ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVES#NYSE">IVES</a>). The <a href="https://www.benzinga.com/etfs/new-etfs/25/06/45774136/wedbush-launches-ai-revolution-etf-backed-by-dan-ives-proprietary-tech-picks">ETF, launched on June 4</a>, managed to <a href="https://www.globenewswire.com/news-release/2025/06/13/3099005/0/en/Dan-IVES-AI-Revolution-ETF-Surpasses-100-Million-AUM-Within-First-Trading-Week-of-Wedbush-Fund-Advisers-Inaugural-Offering.html">pull</a> in $100 million in only five trading days.
IVES &#8220;is built to be disciplined and transparent,&#8221; Wedbush Fund Advisers CIO Cullen Rogers tells Benzinga. &#8220;We don't react to short-term performance or headlines.&#8221;
IVES rebalances quarterly and aligns with revisions to the AI30 model developed by Wedbush&#8217;s Dan Ives, who created the methodology. This frequency steers clear of performance-chasing whiplash from more active managers, while retaining thematic relevance.
The fund &#8220;follows a clear set of rules and reflects the ongoing evolution of Dan's AI30 framework. That combination of research-driven insight alongside a passive index structure gives us the ability to stay focused on the long term,&#8221; Rogers added.
Also Read: <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/06/45978750/why-smart-money-is-spreading-out-etf-flows-signal-surge-in-portfolio-diversification">Why Smart Money Is Spreading Out: ETF Flows Signal Surge In Portfolio Diversification</a>
<h2 class="wp-block-heading">The Case Against Static AI ETFs</h2>
Global X Robotics &amp; Artificial Intelligence ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOTZ#NASDAQ">BOTZ</a>) and ROBO Global Robotics and Automation ETF (ROBO) both have portfolios that lean towards robotics, semiconductors, and infrastructure-heavy hardware. 
BOTZ, for example, has Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>), and Keyence (OTCPK: KYCCF) as its leading holdings. 
ROBO has a strong tilt into industrials and health tech.
But these ETFs tend to be afflicted by static index approaches that fail to adjust rapidly to new AI subsectors like inference engines, generative software, or quantum compute.
<h2 class="wp-block-heading">Inside IVES: A Living Portfolio For A Moving Target</h2>
IVES employs a modified market-cap weighting strategy to keep its biggest bets in check. Yes, it includes the likes of Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Nvidia, and Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>). However, it also leaves room for lesser-known high-conviction picks.
&#8220;We intentionally moved away from traditional straight-line market-cap weighting to avoid exactly that issue (overconcentration and valuation risk tied to the magnificent seven stocks). The modified market-cap weighting approach we use helps large-cap leaders hold influence, but it also prevents them from overwhelming the rest of the portfolio. At the same time, it gives room for smaller, high-conviction names to matter,&#8221; said Rogers.
IVES takes a tight, research-driven approach, Rogers explains. 
"This isn't about market timing — it's about giving investors access to the companies actually building and monetizing the AI revolution, in a format that's disciplined and transparent," he adds.
<h2 class="wp-block-heading">What Happens In A Downturn?</h2>
With valuations across the tech sector under renewed scrutiny, some wonder if AI ETFs are a bubble waiting to pop. Rogers isn't fazed. "Short-term market swings are part of investing, but IVES is built for the long run. What sets the fund apart is its ability to evolve with the AI ecosystem. Not just where it is today, but where it&#8217;s going. That's the advantage of anchoring the portfolio to Dan's ongoing research. As AI matures and new players, platforms, or verticals emerge, the index can adapt," he said.
&#8220;If the center of gravity in AI shifts from semis to inference, or from traditional compute to quantum, Dan's research is positioned to catch that. And our structure is designed to follow it. So even through a downturn, we're confident the fund will stay aligned with the most important parts of the AI value chain as they evolve,&#8221; Rogers emphasized.
Contrast that with holdings such as BOTZ, where old-school industrials and automation stocks constitute a huge percentage of the assets. They&#8217;re exposed to AI, perhaps, but sometimes indirectly and without the agility to change direction quickly.
<h2 class="wp-block-heading">Investor Takeaway: Adaptive &gt; Aggressive</h2>
For individual investors, the message is straightforward: not to conflate AI exposure with AI relevance. BOTZ funds might have expansive baskets, but that expansiveness tends to be at the expense of thematic integrity and forward-looking design. ROBO still stands for its robotics theme and first-mover appeal, but perhaps it will not be the final say on AI innovation as it extends into software.
IVES, on the other hand, presents a more streamlined style that balances conviction with agility. It&#8217;s not attempting to be everywhere, it&#8217;s trying to be where the AI narrative is really headed.
If the previous cycle of AIs revolved around who could train the largest model, perhaps the next will be a question of who can best monetize it. In that game, flexibility, not merely exposure, may be the ultimate advantage.
As Rogers summarizes: &#8220;IVES isn't a static snapshot, it's a living framework.&#8221;
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/06/45975763/risk-on-revival-growth-themed-etfs-hit-52-week-highs-as-market-calms-down">Risk-On Revival: Growth-Themed ETFs Hit 52-Week Highs As Market Calms Down</a></li>
</ul>
Image: Shutterstock

Specialty ETFs

Tech

ETFs

AMZN

BOTZ

ISRG

IVES

KYCCF

MSFT

NVDA

Beyond Magnificent 7: Can Thematic ETFs Like IVES Lead The Next Wave Of AI Investing? CIO Cullen Rogers Explains (CORRECTED)

WIIM

COIN

Coinbase Global shares are trading higher after the company announced it secured an EU crypto license.

Investors with a lot of money to spend have taken a bullish stance on Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with SBUX, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 8 uncommon options trades for Starbucks.
This isn't normal.
The overall sentiment of these big-money traders is split between 37% bullish and 37%, bearish.
Out of all of the special options we uncovered, 4 are puts, for a total amount of $190,344, and 4 are calls, for a total amount of $280,005.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $85.0 to $95.0 for Starbucks over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Starbucks's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Starbucks's substantial trades, within a strike price spectrum from $85.0 to $95.0 over the preceding 30 days.
<h3>Starbucks Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750446098_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBUX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/27/25</td>
<td>$1.15</td>
<td>$1.09</td>
<td>$1.15</td>
<td>$94.00</td>
<td>$126.5K</td>
<td>742</td>
<td>1.4K</td>
</tr>
<tr>
<td>SBUX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$5.55</td>
<td>$5.25</td>
<td>$5.5</td>
<td>$95.00</td>
<td>$82.5K</td>
<td>2.7K</td>
<td>150</td>
</tr>
<tr>
<td>SBUX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$8.05</td>
<td>$7.55</td>
<td>$7.7</td>
<td>$85.00</td>
<td>$77.0K</td>
<td>4.6K</td>
<td>100</td>
</tr>
<tr>
<td>SBUX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$6.25</td>
<td>$6.2</td>
<td>$6.25</td>
<td>$95.00</td>
<td>$54.3K</td>
<td>1.2K</td>
<td>172</td>
</tr>
<tr>
<td>SBUX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$2.25</td>
<td>$2.19</td>
<td>$2.19</td>
<td>$95.00</td>
<td>$42.5K</td>
<td>4.0K</td>
<td>1.2K</td>
</tr>
</tbody>
</table>

<h3>About Starbucks</h3>
Starbucks is one of the most widely recognized restaurant brands in the world, operating more than 40,000 stores across more than 80 countries at the end of March 2025. The firm operates in three segments: North America, international markets, and channel development (grocery and ready-to-drink beverage). The coffee chain generates revenue from company-operated stores, royalties, sales of equipment and products to license partners, ready-to-drink beverages, packaged coffee sales, and single-serve products.
<h3>Where Is Starbucks Standing Right Now?</h3>
<ul>
<li>With a volume of 4,443,349, the price of SBUX is up 1.11% at $93.31. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 39 days.</li>
</ul>
<h3>Expert Opinions on Starbucks</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $93.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from TD Securities downgraded its rating to Hold, setting a price target of $90. 
&#x2A; An analyst from Goldman Sachs has decided to maintain their Neutral rating on Starbucks, which currently sits at a price target of $95. 
&#x2A; An analyst from RBC Capital has decided to maintain their Outperform rating on Starbucks, which currently sits at a price target of $100. 
&#x2A; Reflecting concerns, an analyst from TD Securities lowers its rating to Hold with a new price target of $90. 
&#x2A; In a cautious move, an analyst from TD Securities downgraded its rating to Hold, setting a price target of $90. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Starbucks with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

SBUX

Starbucks Unusual Options Activity

Whales with a lot of money to spend have taken a noticeably bearish stance on Johnson &amp; Johnson.
Looking at options history for Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) we detected 9 trades.
If we consider the specifics of each trade, it is accurate to state that 33% of the investors opened trades with bullish expectations and 66% with bearish.
From the overall spotted trades, 7 are puts, for a total amount of $1,337,900 and 2, calls, for a total amount of $123,232.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $145.0 to $160.0 for Johnson &amp; Johnson during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Johnson &amp; Johnson options trades today is 3709.43 with a total volume of 4,332.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Johnson &amp; Johnson's big money trades within a strike price range of $145.0 to $160.0 over the last 30 days.
<h3>Johnson &amp; Johnson 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750446093_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$10.5</td>
<td>$9.85</td>
<td>$10.25</td>
<td>$160.00</td>
<td>$809.7K</td>
<td>4.0K</td>
<td>790</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$3.25</td>
<td>$3.05</td>
<td>$3.25</td>
<td>$150.00</td>
<td>$256.7K</td>
<td>6.3K</td>
<td>822</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$8.95</td>
<td>$8.9</td>
<td>$8.95</td>
<td>$145.00</td>
<td>$80.5K</td>
<td>2.1K</td>
<td>90</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$10.9</td>
<td>$10.5</td>
<td>$10.9</td>
<td>$160.00</td>
<td>$73.0K</td>
<td>4.0K</td>
<td>1.1K</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$6.7</td>
<td>$6.55</td>
<td>$6.55</td>
<td>$155.00</td>
<td>$65.5K</td>
<td>4.1K</td>
<td>130</td>
</tr>
</tbody>
</table>

<h3>About Johnson &amp; Johnson</h3>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
In light of the recent options history for Johnson &amp; Johnson, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Johnson &amp; Johnson</h3>
<ul>
<li>Trading volume stands at 4,769,606, with JNJ's price down by -0.69%, positioned at $149.69.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 26 days.</li>
</ul>
<h3>Expert Opinions on Johnson &amp; Johnson</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $181.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from RBC Capital has revised its rating downward to Outperform, adjusting the price target to $181. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Johnson &amp; Johnson, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Johnson & Johnson Unusual Options Activity For June 20

Investors with a lot of money to spend have taken a bearish stance on ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with COP, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 9 uncommon options trades for ConocoPhillips.
This isn't normal.
The overall sentiment of these big-money traders is split between 44% bullish and 55%, bearish.
Out of all of the special options we uncovered, 7 are puts, for a total amount of $1,331,295, and 2 are calls, for a total amount of $59,689.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $92.5 and $105.0 for ConocoPhillips, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of ConocoPhillips stands at 2528.0, with a total volume reaching 9,035.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in ConocoPhillips, situated within the strike price corridor from $92.5 to $105.0, throughout the last 30 days.
<h3>ConocoPhillips Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750446088_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>COP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$10.85</td>
<td>$10.85</td>
<td>$10.85</td>
<td>$105.00</td>
<td>$217.0K</td>
<td>3.7K</td>
<td>200</td>
</tr>
<tr>
<td>COP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$11.15</td>
<td>$10.8</td>
<td>$10.85</td>
<td>$105.00</td>
<td>$215.9K</td>
<td>3.7K</td>
<td>1.4K</td>
</tr>
<tr>
<td>COP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$10.95</td>
<td>$10.8</td>
<td>$10.85</td>
<td>$105.00</td>
<td>$215.9K</td>
<td>3.7K</td>
<td>1.0K</td>
</tr>
<tr>
<td>COP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$10.85</td>
<td>$10.8</td>
<td>$10.85</td>
<td>$105.00</td>
<td>$215.9K</td>
<td>3.7K</td>
<td>800</td>
</tr>
<tr>
<td>COP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$10.85</td>
<td>$10.85</td>
<td>$10.85</td>
<td>$105.00</td>
<td>$196.3K</td>
<td>3.7K</td>
<td>1.6K</td>
</tr>
</tbody>
</table>

<h3>About ConocoPhillips</h3>
ConocoPhillips is a US-based independent exploration and production firm. In 2024, it produced 2.0 million barrels per day of oil and natural gas liquids and 3.4 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2024 were 7.8 billion barrels of oil equivalent.
In light of the recent options history for ConocoPhillips, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is ConocoPhillips Standing Right Now?</h3>
<ul>
<li>With a trading volume of 5,169,881, the price of COP is up by 0.33%, reaching $94.11.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 41 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for ConocoPhillips</h3>
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $112.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from B of A Securities continues to hold a Neutral rating for ConocoPhillips, targeting a price of $106. 
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Buy rating on ConocoPhillips with a target price of $115. 
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on ConocoPhillips with a target price of $115. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for ConocoPhillips with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

This Is What Whales Are Betting On ConocoPhillips

Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on EPR Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPR#NYSE">EPR</a>) in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for EPR Props, revealing an average target of $56.71, a high estimate of $65.00, and a low estimate of $53.00. Witnessing a positive shift, the current average has risen by 6.72% from the previous average price target of $53.14.
<img src="https://www.benzinga.com/files/images/story/2025/1750446070_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of EPR Props among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simon Yarmak</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$65.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>John Kilichowski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$53.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>RJ Milligan</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$57.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Michael Carroll</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$58.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Ki Bin Kim</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$55.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Michael Goldsmith</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$56.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Ki Bin Kim</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$53.00</td>
<td>$51.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to EPR Props. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of EPR Props compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of EPR Props's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EPR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on EPR Props analyst ratings.</a>
<h2>Discovering EPR Props: A Closer Look</h2>
EPR Properties is a real estate investment trust that focuses on underwriting experiential property investments on key industry and property cash flow criteria, and the credit metrics of tenants and customers. The company invests in two property segments: Experiential, including theaters, family entertainment centers, ski resorts, and other attractions; and Education, including early childhood education centers and private school properties. The Company's business is focused on Experiential real estate. The majority of revenue comes from the Experiential sector.
<h3>Unraveling the Financial Story of EPR Props</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Positive Revenue Trend: Examining EPR Props's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 5.29% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 36.58%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): EPR Props's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.57% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): EPR Props's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.07% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 1.3, EPR Props adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

What 7 Analyst Ratings Have To Say About EPR Props

During the last three months, 3 analysts shared their evaluations of Commercial Metals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMC#NYSE">CMC</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Commercial Metals, presenting an average target of $51.33, a high estimate of $53.00, and a low estimate of $49.00. This current average has increased by 0.65% from the previous average price target of $51.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1750446058_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Commercial Metals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Piyush Sood</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$53.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Bill Peterson</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Neutral</td>
<td>$52.00</td>
<td>-</td>
</tr>
<tr>
<td>Curt Woodworth</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$49.00</td>
<td>$54.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Commercial Metals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Commercial Metals compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Commercial Metals's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Commercial Metals's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CMC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Commercial Metals analyst ratings.</a>
<h2>Get to Know Commercial Metals Better</h2>
Commercial Metals Co operates steel mills, steel fabrication plants, and metal recycling facilities in the United States and manufactures rebar and structural steel, which are key product categories for the nonresidential construction sector. The Company has three operating and reportable segments: North America Steel Group, Europe Steel Group and Emerging Businesses Group.
<h3>Commercial Metals's Economic Impact: An Analysis</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Negative Revenue Trend: Examining Commercial Metals's financials over 3M reveals challenges. As of 28 February, 2025, the company experienced a decline of approximately -5.08% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Materials sector.
Net Margin: Commercial Metals's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.45% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Commercial Metals's ROE excels beyond industry benchmarks, reaching 0.63%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Commercial Metals's ROA excels beyond industry benchmarks, reaching 0.38%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.3.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Commercial Metals: Insights From 3 Financial Analysts

Across the recent three months, 4 analysts have shared their insights on Groupon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPN#NASDAQ">GRPN</a>), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Groupon, presenting an average target of $30.25, a high estimate of $47.00, and a low estimate of $15.00. Witnessing a positive shift, the current average has risen by 30.11% from the previous average price target of $23.25.
<img src="https://www.benzinga.com/files/images/story/2025/1750446049_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The perception of Groupon by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sean McGowan</td>
<td>Roth Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$47.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Bobby Brooks</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Outperform</td>
<td>$35.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Sell</td>
<td>$15.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Sean McGowan</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$24.00</td>
<td>$21.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Groupon. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Groupon compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Groupon's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Groupon's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/GRPN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Groupon analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Groupon's Background</h2>
Groupon Inc acts as the middleman between consumers and merchants, offering products and services at discounts via its online store. It offers consumers daily deals from local merchants. The company's operations are organized into two segments: North America and International. The company generates the majority of its revenue from North America. The company generates revenue from transactions during which the company generates commissions by selling goods or services on behalf of third-party merchants. Revenue also includes commissions the company earn when customers make purchases with retailers using digital coupons accessed through its digital properties.
<h3>Understanding the Numbers: Groupon's Finances</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Negative Revenue Trend: Examining Groupon's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -4.79% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 6.12%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Groupon's ROE stands out, surpassing industry averages. With an impressive ROE of 16.63%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Groupon's ROA stands out, surpassing industry averages. With an impressive ROA of 1.18%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Groupon's debt-to-equity ratio surpasses industry norms, standing at 5.56. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GRPN

Where Groupon Stands With Analysts

Devon Energy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) short percent of float has fallen 8.95% since its last report. The company recently reported that it has 16.64 million shares sold short, which is 2.95% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.05 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Devon Energy Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750446038_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Devon Energy has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Devon Energy's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Devon Energy's peer group average for short interest as a percentage of float is 8.75%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Devon Energy?

Throughout the last three months, 5 analysts have evaluated GMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMS#NYSE">GMS</a>), offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for GMS, revealing an average target of $96.04, a high estimate of $105.00, and a low estimate of $90.00. This current average reflects an increase of 24.4% from the previous average price target of $77.20. 
<img src="https://www.benzinga.com/files/images/story/2025/1750446035_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of GMS by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keith Hughes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$105.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Sam Darkatsh</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Matthew Bouley</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$95.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Mike Dahl</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$95.20</td>
<td>$65.00</td>
</tr>
<tr>
<td>Trey Grooms</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$95.00</td>
<td>$90.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to GMS. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of GMS compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of GMS's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/GMS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on GMS analyst ratings.</a>
<h2>All You Need to Know About GMS</h2>
GMS Inc is a distributor of specialty building products including wallboard, suspended ceiling systems, ceilings, steel framing, and other complementary building products. The company serves its products to commercial new construction, commercial repair and remodel, residential new construction, and residential repair and remodel (R&amp;R). Its geographical segment is Central, Midwest, New York, Northeast, Southern, Southeast, Southwest, Western and Canada. The company generates maximum revenue from Wallboard products.
<h3>Financial Milestones: GMS's Journey</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Challenges: GMS's revenue growth over 3M faced difficulties. As of 30 April, 2025, the company experienced a decline of approximately -5.61%. This indicates a decrease in top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: GMS's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 1.96%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 1.85%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): GMS's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.68%, the company may face hurdles in achieving optimal financial returns.
Debt Management: GMS's debt-to-equity ratio is below the industry average at 1.13, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: GMS Through The Eyes Of 5 Analysts

Sony Gr's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) short percent of float has risen 35.71% since its last report. The company recently reported that it has 11.65 million shares sold short, which is 0.19% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.76 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Sony Gr Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750446033_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Sony Gr has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Sony Gr's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Sony Gr's peer group average for short interest as a percentage of float is 4.90%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Sony Group Corporation American Depositary Shares

SONY

Peering Into Sony Gr's Recent Short Interest

BrightSpring Health's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTSG#NYSE">BTSG</a>) short percent of float has risen 5.09% since its last report. The company recently reported that it has 11.37 million shares sold short, which is 21.48% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.9 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>BrightSpring Health Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750446028_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for BrightSpring Health has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing BrightSpring Health's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, BrightSpring Health's peer group average for short interest as a percentage of float is 8.49%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

BTSG

What's Driving the Market Sentiment Around BrightSpring Health?

In the current session, the stock is trading at $85.04, after a 0.94% spike. Over the past month, American International Gr Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>) stock increased by 3.89%, and in the past year, by 11.56%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1750446027_0.png" alt="Past Year Chart" />

<h3>A Look at American International Gr P/E Relative to Its Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
American International Gr has a lower P/E than the aggregate P/E of 22.88 of the Insurance industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1750446027_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

P/E Ratio Insights for American International Gr

Analysts' ratings for Adeia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADEA#NASDAQ">ADEA</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $19.75, a high estimate of $26.00, and a low estimate of $17.00. This current average reflects an increase of 11.77% from the previous average price target of $17.67. 
<img src="https://www.benzinga.com/files/images/story/2025/1750446022_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Adeia is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scott Searle</td>
<td>Roth Capital</td>
<td>Announces</td>
<td>Buy</td>
<td>$26.00</td>
<td>-</td>
</tr>
<tr>
<td>Hamed Khorsand</td>
<td>BWS Financial</td>
<td>Maintains</td>
<td>Buy</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$17.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Hamed Khorsand</td>
<td>BWS Financial</td>
<td>Maintains</td>
<td>Buy</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Adeia. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Adeia compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Adeia's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Adeia's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ADEA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Adeia analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Adeia's Background</h2>
Adeia Inc is a consumer and entertainment product/solutions licensing company. Its only operating segment being Intellectual Property (IP) Licensing. In the IP segment, it primarily license innovations to leading companies in the broader entertainment industry, and those developing new technologies that will help drive this industry forward. It includes Pay-TV, Consumer Electronics, Connected Car, and Media Platform.
<h3>Financial Milestones: Adeia's Journey</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Adeia displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 5.11%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Adeia's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 13.48% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Adeia's ROE excels beyond industry benchmarks, reaching 3.01%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Adeia's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.08% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Adeia's debt-to-equity ratio is below the industry average. With a ratio of 1.2, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADEA

Breaking Down Adeia: 4 Analysts Share Their Views

In the last three months, 5 analysts have published ratings on Cleveland-Cliffs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>), offering a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Cleveland-Cliffs, presenting an average target of $9.23, a high estimate of $17.00, and a low estimate of $3.91. This current average represents a 15.17% decrease from the previous average price target of $10.88. 
<img src="https://www.benzinga.com/files/images/story/2025/1750446013_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Cleveland-Cliffs. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carlos De Alba</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$8.00</td>
<td>$7.50</td>
</tr>
<tr>
<td>Christopher LeFemina</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$6.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Gordon Johnson</td>
<td>GLJ Research</td>
<td>Maintains</td>
<td>Sell</td>
<td>$3.91</td>
<td>$3.91</td>
</tr>
<tr>
<td>Mike Harris</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$11.25</td>
<td>$13.00</td>
</tr>
<tr>
<td>Nick Giles</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$17.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Cleveland-Cliffs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Cleveland-Cliffs compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Cleveland-Cliffs's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Cleveland-Cliffs's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CLF/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Cleveland-Cliffs analyst ratings.</a>
<h2>Unveiling the Story Behind Cleveland-Cliffs</h2>
Cleveland-Cliffs Inc is a flat-rolled steel producer and manufacturer of iron ore pellets in North America. It is organized into four operating segments based on differentiated products, Steelmaking, Tubular, Tooling and Stamping and European Operations, but operates through one reportable segment -Steelmaking. It is vertically integrated from mined raw materials, direct reduced iron, and ferrous scrap to primary steelmaking and downstream finishing, stamping, tooling and tubing. It serves a diverse range of other markets due to its comprehensive offering of flat-rolled steel products. Geographically, it operates in the United States, Canada and other countries. The majority of revenue is from the United States. It is a supplier of steel to the automotive industry in North America.
<h3>Cleveland-Cliffs's Economic Impact: An Analysis</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Decline in Revenue: Over the 3M period, Cleveland-Cliffs faced challenges, resulting in a decline of approximately -10.96% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Materials sector.
Net Margin: Cleveland-Cliffs's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -10.69%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Cleveland-Cliffs's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -7.66%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Cleveland-Cliffs's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -2.37%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Cleveland-Cliffs's debt-to-equity ratio stands notably higher than the industry average, reaching 1.22. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Cleveland-Cliffs Stands With Analysts

<a href="https://www.ft.com/content/53f646e7-b4e7-4bf4-8d5d-7142b4460080">https://www.ft.com/content/53f646e7-b4e7-4bf4-8d5d-7142b4460080</a>

Politics

'Japan scraps US meeting after Washington demands more defence spending'- Financial Times

BofA Securities analyst Anna Lizzul reiterated the Buy rating on e.l.f. Beauty, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>), <a href="https://www.benzinga.com/quote/ELF/analyst-ratings" target="_blank" rel="noreferrer noopener">raising the price forecast from $113 to $135.</a>
Lizzul revised the first-quarter sales estimate to +12% from the previous +15%, citing early-quarter softness in scanner data. She also lowered the gross margin forecast to 69% from 70% due to tariff impacts that were not yet offset by price increases scheduled for Aug. 1.
The analyst also projects non-marketing SG&amp;A growth to exceed the rate of sales growth in the first quarter. As a result, the first-quarter EBITDA estimate is reduced to $69 million from $90 million.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/entertainment/25/06/45889752/hollywood-has-a-new-take-on-the-phone-plan-meet-smartless-mobile" rel="noreferrer noopener">Hollywood Has A New Take On The Phone Plan&#8211;Meet SmartLess Mobile</a>
Looking beyond the first quarter, Lizzul sees potential for sales acceleration and gross margin improvement driven by the upcoming price increases, cost savings, and possible supplier concessions.
Lizzul projects e.l.f. Beauty to issue fiscal 2026 guidance in August, which wasn't provided during the fourth-quarter earnings call.
The timing will likely follow greater clarity around tariffs, the Aug. 1 pricing implementation, and the expected closing of the Rhode acquisition.
As fiscal 2026 progresses, the analyst anticipates potential upside to revenue and margin estimates, supported by stronger-than-expected volume resilience, pricing gains, new product launches enhancing price/mix, and the integration of Rhode.
Lizzul noted that the Rhode acquisition positions e.l.f. Beauty in the prestige segment, with the deal expected to close by the end of the second quarter.
The acquisition is projected to be accretive to sales, margins, and earnings within the first year.
Rhode offers strong growth potential, especially in international markets, which currently make up about 20% of its direct-to-consumer sales but account for 74% of its social media following.
The brand is expected to launch first in Sephora stores abroad, helping differentiate it from e.l.f.&#8217;s core offerings, which are not sold at Sephora outside of Mexico.
Price Action: ELF shares are trading lower by 4.07% to $117.26 at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46023273/walmart-snaps-10-day-losing-streak-its-longest-since-2004-as-profit-takers-step-aside" target="_blank" rel="noreferrer noopener">Walmart Snaps 10-Day Losing Streak: It&#8217;s Longest Since 2004, As Profit-Takers Step Aside</a></li>
</ul>
Image: Shutterstock

E.l.f. Beauty Analyst Sees Upside From Price Hikes, Cost Savings, And Rhode Integration Despite Tariff Impacts

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted on Friday a positive opinion recommending approval for Madrigal Pharmaceuticals, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGL#NASDAQ">MDGL</a>) resmetirom (Rezdiffra) for adults with noncirrhotic MASH with moderate to <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">advanced liver fibrosis</a>.
EMA <a href="https://www.ema.europa.eu/en/news/first-treatment-against-liver-scarring-caused-type-fatty-liver-disease" target="_blank" rel="noreferrer noopener">has</a> recommended granting a conditional marketing authorization, <a href="https://www.globenewswire.com/news-release/2025/05/10/3078638/0/en/Madrigal-Announces-New-Clinical-Data-Demonstrating-Rezdiffra-resmetirom-Significantly-Improved-Multiple-Noninvasive-Tests-and-Portal-Hypertension-Risk-in-Patients-with-Compensated-.html?_gl=1&#x2A;v9i9of&#x2A;_gcl_au&#x2A;MTgxMjM4ODIyNy4xNzUwMDg5NzEz&#x2A;_ga&#x2A;MTMzODE1NTQwNC4xNzM0MzgyMDk4&#x2A;_ga_MBTGG7KX5Y&#x2A;czE3NTA0NDUyNDkkbzQ1MiRnMSR0MTc1MDQ0NTU4NCRqNjAkbDAkaDExNjcwNDQzNDI.">said</a> a press release.
The European Commission decision is anticipated in August.
Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), is a serious liver disease that can progress to cirrhosis, liver failure, liver cancer, need for liver transplantation <a href="https://www.benzinga.com/pressreleases/25/06/g46021876/madrigal-receives-positive-chmp-opinion-for-resmetirom-rezdiffra-for-the-treatment-of-mash-with-mo" target="_blank" rel="noreferrer noopener">and premature mortality</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43981624/madrigal-pharmaceuticals-stock-jumps-on-new-two-year-data-showing-potential-benefit-of-rezdiffra-for-compensated-fatty-liver-cirrhosis" rel="noreferrer noopener">Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis</a>
The CHMP opinion was based on resmetirom&#8217;s favorable profile, including the positive results from the pivotal&nbsp;Phase 3 MAESTRO-NASH trial, which achieved both fibrosis reduction and MASH resolution primary endpoints.
The U.S. Food and Drug Administration (FDA) granted accelerated approval in March 2024 for Rezdiffra in conjunction with diet and exercise for the treatment of adults with noncirrhotic MASH with moderate to <a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37751655/fda-conditionally-approves-madrigal-pharmaceuticals-resmetirom-as-first-treatment-for-fatty-liver" rel="noreferrer noopener">advanced liver fibrosis</a>.
Continued approval for this indication may be contingent upon verification and description of clinical benefit in ongoing confirmatory trials.
In May, Madrigal Pharmaceuticals announced two-year results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45335059/madrigal-announces-new-clinical-data-demonstrating-rezdiffra-resmetirom-significantly-improved-mul" rel="noreferrer noopener">trial of Rezdiffra</a>.
Patients (n=122) in the study achieved significant improvements from baseline in liver stiffness, liver fat, fibrosis biomarkers, liver volume and risk scores for clinically significant portal hypertension (CSPH).
MAESTRO-NAFLD-1 included an open-label active treatment arm of patients with compensated MASH cirrhosis.
Among patients with CSPH at baseline, 65% moved into lower-risk categories by year two (42% to no/low CSPH and 23% to probable CSPH). Among patients with probable CSPH at baseline, 57% moved into the no/low CSPH category as compared to 14% who moved into the CSPH category by year two.
Improvement in CSPH risk was statistically significant compared to baseline.
As previously reported, patients achieved a mean 6.7 kPa reduction in liver stiffness at two years, statistically significant compared to baseline. In a responder analysis examining ≥25% improvement or worsening of liver stiffness, 51% of patients achieved improvement.
An improvement of this magnitude has been associated with reduced progression to end-stage liver disease.
Rezdiffra helped 35% of patients achieve liver stiffness measurements consistent with F3 fibrosis, suggesting reversal of cirrhosis.
The company generated first-quarter 2025 net revenues of $137.3 million. No product sales were recognized during the comparable <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45129596/madrigal-pharmaceuticals-reports-first-quarter-2025-financial-results-and-provides-corporate-updat" rel="noreferrer noopener">prior year period</a>.
MDGL Price Action: Madrigal Pharmaceuticals stock is up 0.33% at $283.66 at publication on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/biotech/25/05/45406673/gsk-to-buy-phase-3-ready-liver-disease-drug-for-up-to-2-billion" target="_blank" rel="noreferrer noopener">GSK To Buy Phase-3 Ready Liver Disease Drug For Up To $2 Billion</a></li>
</ul>
Photo: Shutterstock

Large Cap

Global

MDGL

European Advisory Panel Backs Conditional Approval For Madrigal's Fatty Liver Disease Drug

Press Releases

Equinox Gold Announces Filing and Mailing of Meeting Materials for the Annual & Special Meeting of Shareholders on April 24, 2025

Equinox Gold Provides Update on the Los Filos Mine

Equinox Gold Shareholders Receive Positive Voting Recommendations for Business Combination with Calibre Mining

Equinox Gold and Calibre Mining Amend Arrangement Agreement in Respect of Proposed Business Combination, Announce Adjournment of Respective Shareholder Meetings, New Meeting Dates Set for May 1, 2025

Equinox Gold to Announce First Quarter Financial and Operating Results on May 7, 2025

Calibre Securityholders Approve Business Combination with Equinox Gold

Equinox Gold Announces Results from Adjourned Annual & Special Meeting of Shareholders: Shareholders Approve Business Combination with Calibre Mining

Equinox Gold Reports First Quarter 2025 Financial and Operating Results

Equinox Gold Provides Updated 2025 Gold Production and Cost Guidance, 2025 Full-year Pro Forma Guidance, Including Calibre Mining Assets, of 785,000 - 915,000 Ounces of Gold, Greenstone Mine Expecting Strong H2 2025

Comments

Equinox Gold

Noticias

Últimas noticias sobre Equinox Gold (AMEX:EQX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL